UK markets open in 6 hours 36 minutes
NIKKEI 225
38,798.41 +11.03 (+0.03%) HANG SENG
19,553.61 +177.11 (+0.91%) CRUDE OIL
79.73 -0.33 (-0.41%) GOLD FUTURES
2,422.00 +4.60 (+0.19%) DOW
40,003.59 +134.19 (+0.34%) Bitcoin GBP
52,122.04 -582.21 (-1.10%)
Arbutus Biopharma Corp (I9DN.SG)
Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
At close: 09:59PM CEST
| Previous close | 2.5980 |
| Open | 2.6020 |
| Bid | 2.6800 x 200000 |
| Ask | 2.7740 x 200000 |
| Day's range | 2.6020 - 2.7080 |
| 52-week range | 1.5340 - 3.0000 |
| Volume | |
| Avg. volume | 110 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript May 2, 2024 Arbutus Biopharma Corporation misses on earnings expectations. Reported EPS is $-0.10178 EPS, expectations were $-0.1. Arbutus Biopharma Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, […]
- Simply Wall St.
Arbutus Biopharma First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Arbutus Biopharma ( NASDAQ:ABUS ) First Quarter 2024 Results Key Financial Results Revenue: US$1.53m (down 77% from 1Q...
- GuruFocus.com
Arbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Insights into Arbutus Biopharma Corp's Q1 performance, including financial updates and progress in clinical trials.
© 2024 Yahoo. All rights reserved.